Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Ex-AstraZeneca Leader Spies Opening In SERD Field
Executive Summary
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’
You may also be interested in...
Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs
Restructuring Edition: After reporting record revenue, but lower profits due to rising costs, Ferring has decided to consolidate R&D in Europe. Also, Codiak has filed for Chapter 11 bankruptcy and will sell off its assets, while Exicure, Applied Molecular Transport, Gamida Cell and others revealed new job cuts.
Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
Arvinas And Pfizer’s Protein Degrader Shows Mixed Results In Breast Cancer
The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.